SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

UX143

RARE·Ultragenyx Pharmaceutical Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 3 (completed)
Time to market
Uncertain. The drug failed its Phase 3 primary endpoints. Ultragenyx and partner Mereo are in discussions with FDA, EMA, and UK regulators about a potential path forward, particularly in pediatric patients. No regulatory submission has been announced and no PDUFA date exists. Regulatory feedback is expected by year-end 2026.
Why 3/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. The defining binary event (Phase 3 topline readout) already occurred in December 2025 and was negative. The next catalyst is regulatory feedback from ongoing FDA/EMA discussions, which is not a hard dated binary. Setrusumab is one of several pipeline programs at a company with six approved products and multiple other late-stage assets.
Actionable Insight BEARISH

Watch for regulatory feedback from FDA/EMA discussions expected by year-end 2026, which will determine whether setrusumab has a viable path to approval despite the primary endpoint miss. The key question is whether regulators will accept bone mineral density improvements as a surrogate for fracture reduction in pediatric OI patients. A negative regulatory signal would likely end the program; a positive signal could open a narrow approval pathway.

Price Chart

Loading chart...

Executive Summary

UX143 (setrusumab) is an investigational antibody for osteogenesis imperfecta (brittle bone disease) developed by Ultragenyx Pharmaceutical (RARE) in partnership with Mereo BioPharma. In December 2025, two Phase 3 trials (Orbit and Cosmic) both failed their primary endpoints of reducing fracture rates, causing RARE stock to drop ~43-45%. The drug did show statistically significant improvements in bone mineral density. Ultragenyx spared setrusumab from its November 2026 pipeline cuts and, with Mereo, is in discussions with FDA, EMA, and UK regulators about a potential path forward, particularly in pediatric patients. No regulatory submission has been made and no PDUFA date exists. The drug's future is highly uncertain.

How It Works

Setrusumab is a lab-made antibody that blocks sclerostin, a protein that normally puts the brakes on bone formation. By blocking sclerostin, the drug aims to stimulate the body to build new bone, increasing bone density and strength. It is given as an intravenous infusion.

Trial Status

Two global Phase 3 trials (Orbit in ages 5-25, Cosmic in ages 2 to <7) completed in December 2025. Both missed their primary endpoints (reduction in annualized clinical fracture rate vs placebo or bisphosphonates). Both achieved the secondary endpoint of statistically significant improvements in bone mineral density. Pre-specified and post-hoc analyses were presented at the ASBMR 2026 annual meeting showing "meaningful benefit on bone mineral density, fractures, and other endpoints." A small Phase 3 study in Japanese pediatric patients (NCT06636071, n=6) is active but not recruiting, with primary completion estimated January 2027.

The Two-Sided Case

▲ Bull Case4
Setrusumab was spared from Ultragenyx's November 2026 restructuring that cut 20% of staff and axed other pipeline programs, signaling the company still sees potential value
The drug achieved strong, statistically significant improvements in bone mineral density (a key secondary endpoint) in both Phase 3 studies, and post-hoc analyses presented at ASBMR 2026 showed meaningful fracture benefits
FDA granted Breakthrough Therapy Designation in October 2024, which could facilitate a more flexible regulatory review even after the primary endpoint miss
OI affects approximately 60,000 people in commercially accessible geographies with no approved disease-modifying therapy globally, representing a large unmet need
▼ Bear Case5
Both Phase 3 trials (Orbit and Cosmic) failed their primary endpoints of reducing annualized clinical fracture rate, the most clinically meaningful metric for OI patients
Ultragenyx stock lost ~43-45% of its value on the December 29, 2025 readout, erasing over $1 billion in market cap
Multiple analysts downgraded the stock (JP Morgan, William Blair, Evercore, Baird) and several trimmed price targets following the failure
The regulatory path forward is highly uncertain; bone mineral density as a surrogate endpoint for fracture reduction has not been validated by regulators for OI
Ultragenyx is in cost-cutting mode (20% workforce reduction, targeting 2027 profitability), which may limit further investment in a program with negative pivotal data

Upcoming Catalysts

  • Regulatory feedback from FDA/EMA/UK discussions on a potential path forward for setrusumab in pediatric OI patients (expected by year-end 2026 per Mereo Q2 2026 update)
  • Primary completion of small Phase 3 study in Japanese pediatric OI patients (estimated January 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ultragenyx Pharmaceutical Inc. PRESS-RELEASE RARE ·Originating report

Sources · 11

Hover a chip for the title
1 ir.ultragenyx.com2 biospace.com3 nasdaq.com4 biospace.com5 fiercebiotech.com6 insights.citeline.com7 mereobiopharma.com8 mereobiopharma.com9 ir.ultragenyx.com10 ultragenyx.com11 biospace.com